There is no cure for chronic lymphocytic leukemia, but an array of new therapeutic strategies are improving outcomes for patients. The treatment of chronic lymphocytic leukemia (CLL) has evolved ...
Please provide your email address to receive an email when new articles are posted on . Pirtobrutinib significantly improved PFS for patients with CLL and SLL compared with standard chemoimmunotherapy ...
Continuous and fixed-duration treatments result in similar outcomes for chronic lymphocytic leukemia
According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed ...
A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to living their lives to the fullest after being diagnosed with chronic ...
Anticipating the 2025 American Society of Hematology Annual Meeting and Exposition, Suchitra Sundaram, MD, reviews several clinical trials in chronic lymphocytic leukemia (CLL) that will present data ...
Lymphocytic colitis is a bowel condition characterized by chronic, watery diarrhea and the buildup of white blood cells in your gut. It is most common in older adults. Lymphocytic colitis is a rare ...
Please provide your email address to receive an email when new articles are posted on . Serious infections in patients with chronic lymphocytic leukemia have doubled despite increased use of ...
Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...
One study found that a low level of fitness poses a greater risk of death over time than other traditional risk factors ...
Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...
Findings showed pirtobrutinib was noninferior to ibrutinib in both the pre-treated and intent-to-treat populations for the endpoint of ORR. Topline data were announced from a head-to-head phase 3 ...
Senior Lecturer of Exercise Immunology, Faculty of Health and Medical Sciences, School of Biosciences, University of Surrey CLL starts when a type of immune cell called a B cell – normally responsible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback